Pharmaceuticals, Biotechnology and Life Sciences
Keytruda/lenvima combination treatment has been approved for certain patients with advanced endometrial carcinoma which isn’t Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR)
Merck has ensured Breakthrough Therapy Designation for the investigational targeted therapy tepotinib in USA, for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations who progressed following platinum-based cancer therapy.
Merck, a leading science and technology company, today announced the initiation of two global pivotal Phase III trials (EVOLUTION RMS 1 and 2) studying the efficacy and safety of evobrutinib, an oral, highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor in adult patients with relapsing multiple sclerosis (RMS).
BerGenBio will have two presentations to highlight its Phase II clinical trial with bemcentinib and Merck’s anti-PD-1 therapy Keytruda in patients with advanced non-small cell lung cancer (NSCLC), which showed promising clinical activity overall.
Designation Granted for Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment KENILWORTH, N.J.…
U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) voted to recommend HPV vaccination with GARDASIL
Phase 1/2 clinical trial to evaluate Intensity’s INT230-6 in combination with KEYTRUDA® (pembrolizumab) for multiple solid tumor types
Keytruda’s market potential in this indication remains limited due to its approval for primary mediastinal B-cell lymphoma (PMBCL), which only accounts for a small percentage of non-Hodgkin’s lymphoma (NHL) patients.
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Osteoarthritis” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the Osteoarthritis market,…
Syntrix Pharmaceuticals has started its Phase 1/2 clinical trial that will combine SX-682 with KEYTRUDA, Merck’s anti-PD-1 therapy, as it dosed the first patient, it said Thursday.